{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:27:04Z","timestamp":1789453624317,"version":"build-2803163510"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Since its emergence in the 1960s, the serotonergic theory of depression bore fruit in the discovery of a plethora of antidepressant drugs affecting the lives of millions of patients. While crucial in the history of drug development, recent studies undermine the effectiveness of currently used antidepressant drugs in comparison to placebo, emphasizing the long time it takes to initiate the therapeutic response and numerous adverse effects. Thus, the scope of contemporary pharmacological research shifts from drugs affecting the serotonin system to rapid-acting antidepressant drugs. The prototypical representative of the aforementioned class is ketamine, an NMDA receptor antagonist capable of alleviating the symptoms of depression shortly after the drug administration. This discovery led to a paradigm shift, focusing on amino-acidic neurotransmitters and growth factors. Alas, the drug is not perfect, as its therapeutic effect diminishes circa 2\u00a0weeks after administration. Furthermore, it is not devoid of some severe side effects. However, there seems to be another, more efficient, and safer way to target the glutamatergic system. Hallucinogenic agonists of the 5-HT<jats:sub>2A<\/jats:sub> receptor, commonly known as psychedelics, are nowadays being reconsidered in clinical practice, shedding their infamous 1970s stigma. More and more clinical studies prove their clinical efficacy and rapid onset after a single administration while bearing fewer side effects. This review focuses on the current state-of-the-art literature and most recent clinical studies concerning the use of psychedelic drugs in the treatment of mental disorders. Specifically, the antidepressant potential of LSD, psilocybin, DMT, and 5-MeO-DMT will be discussed, together with a brief summary of other possible applications.<\/jats:p>","DOI":"10.1007\/s43440-023-00550-9","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T06:01:25Z","timestamp":1699336885000},"page":"1313-1325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The possible place for psychedelics in pharmacotherapy of mental disorders"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7785-8396","authenticated-orcid":false,"given":"Adam","family":"Wojtas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"issue":"1","key":"550_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12888-020-02546-8","volume":"20","author":"A Steffen","year":"2020","unstructured":"Steffen A, N\u00fcbel J, Jacobi F, B\u00e4tzing J, Holstiege J. Mental and somatic comorbidity of depression: a comprehensive cross-sectional analysis of 202 diagnosis groups using German nationwide ambulatory claims data. BMC Psychiatry. 2020;20(1):142. https:\/\/doi.org\/10.1186\/s12888-020-02546-8.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"550_CR2","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1038\/s41598-018-21243-x","volume":"8","author":"GY Lim","year":"2018","unstructured":"Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8(1):2861. https:\/\/doi.org\/10.1038\/s41598-018-21243-x.","journal-title":"Sci Rep"},{"issue":"10312","key":"550_CR3","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","unstructured":"COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(21)02143-7.","journal-title":"Lancet"},{"key":"550_CR4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.","edition":"5"},{"issue":"3","key":"550_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nm.4050","volume":"22","author":"RS Duman","year":"2016","unstructured":"Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238\u201349. https:\/\/doi.org\/10.1038\/nm.4050.","journal-title":"Nat Med"},{"issue":"1","key":"550_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41380-022-01806-1","volume":"28","author":"GR Fries","year":"2023","unstructured":"Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder converge on the synapse. Mol Psychiatry. 2023;28(1):284\u201397. https:\/\/doi.org\/10.1038\/s41380-022-01806-1.","journal-title":"Mol Psychiatry"},{"issue":"81\u2013109","key":"550_CR7","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1146\/annurev.psych.093008.100321","volume":"61","author":"F Holsboer","year":"2010","unstructured":"Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol. 2010;61(81\u2013109):C1\u201311. https:\/\/doi.org\/10.1146\/annurev.psych.093008.100321.","journal-title":"Annu Rev Psychol"},{"issue":"7215","key":"550_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/nature07455","volume":"455","author":"V Krishnan","year":"2008","unstructured":"Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894\u2013902. https:\/\/doi.org\/10.1038\/nature07455.","journal-title":"Nature"},{"issue":"1","key":"550_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1073\/pnas.0706679105","volume":"105","author":"RJ Liu","year":"2008","unstructured":"Liu RJ, Aghajanian GK. Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci USA. 2008;105(1):359\u201364. https:\/\/doi.org\/10.1073\/pnas.0706679105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"550_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0306-4522(95)00259-l","volume":"69","author":"AM Magari\u00f1os","year":"1995","unstructured":"Magari\u00f1os AM, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neuroscience. 1995;69(1):89\u201398. https:\/\/doi.org\/10.1016\/0306-4522(95)00259-l.","journal-title":"Neuroscience"},{"issue":"9","key":"550_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1101\/lm.037291.114","volume":"22","author":"EJ Kim","year":"2015","unstructured":"Kim EJ, Pellman B, Kim JJ. Stress effects on the hippocampus: a critical review. Learn Mem. 2015;22(9):411\u20136. https:\/\/doi.org\/10.1101\/lm.037291.114.","journal-title":"Learn Mem"},{"issue":"6","key":"550_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/archpsyc.1965.01730060001001","volume":"13","author":"WE Bunney Jr","year":"1965","unstructured":"Bunney WE Jr, Davis JM. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry. 1965;13(6):483\u201394. https:\/\/doi.org\/10.1001\/archpsyc.1965.01730060001001.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 6","key":"550_CR13","first-page":"7","volume":"61","author":"PL Delgado","year":"2000","unstructured":"Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61(Suppl 6):7\u201311.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 6","key":"550_CR14","first-page":"4","volume":"61","author":"RM Hirschfeld","year":"2000","unstructured":"Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry. 2000;61(Suppl 6):4\u20136.","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"550_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1176\/ajp.122.5.509","volume":"122","author":"JJ Schildkraut","year":"1965","unstructured":"Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509\u201322. https:\/\/doi.org\/10.1176\/ajp.122.5.509.","journal-title":"Am J Psychiatry"},{"issue":"505","key":"550_CR16","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1192\/bjp.113.505.1407","volume":"113","author":"DM Shaw","year":"1967","unstructured":"Shaw DM, Camps FE, Eccleston EG. 5-Hydroxytryptamine in the hind-brain of depressive suicides. Br J Psychiatry. 1967;113(505):1407\u201311. https:\/\/doi.org\/10.1192\/bjp.113.505.1407.","journal-title":"Br J Psychiatry"},{"issue":"3","key":"550_CR17","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/01.hyp.28.3.414","volume":"28","author":"M Mahata","year":"1996","unstructured":"Mahata M, Mahata SK, Parmer RJ, O\u2019Connor DT. Vesicular monoamine transport inhibitors. Novel action at calcium channels to prevent catecholamine secretion. Hypertension. 1996;28(3):414\u201320. https:\/\/doi.org\/10.1161\/01.hyp.28.3.414.","journal-title":"Hypertension"},{"issue":"9","key":"550_CR18","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1001\/jama.1955.02960260006002","volume":"159","author":"JC Muller","year":"1955","unstructured":"Muller JC, Pryor WW, Gibbons JE, Orgain ES. Depression and anxiety occurring during Rauwolfia therapy. J Am Med Assoc. 1955;159(9):836\u20139. https:\/\/doi.org\/10.1001\/jama.1955.02960260006002.","journal-title":"J Am Med Assoc"},{"issue":"1","key":"550_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/diagnostics11010123","volume":"11","author":"M Becker","year":"2021","unstructured":"Becker M, Pinhasov A, Ornoy A. Animal models of depression: what can they teach us about the human disease? Diagnostics (Basel). 2021;11(1):123. https:\/\/doi.org\/10.3390\/diagnostics11010123.","journal-title":"Diagnostics (Basel)"},{"issue":"3498","key":"550_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1126\/science.135.3498.107","volume":"135","author":"N Kirshner","year":"1962","unstructured":"Kirshner N. Uptake of catecholamines by a particulate fraction of the adrenal medulla. Science. 1962;135(3498):107\u20138. https:\/\/doi.org\/10.1126\/science.135.3498.107.","journal-title":"Science"},{"issue":"3","key":"550_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1749-6632.1957.tb40751.x","volume":"66","author":"PA Shore","year":"1957","unstructured":"Shore PA, Pletscher A, Tomich EG, Carlsson A, Kuntzman R, Brodie BB. Role of brain serotonin in reserpine action. Ann N Y Acad Sci. 1957;66(3):609\u201315. https:\/\/doi.org\/10.1111\/j.1749-6632.1957.tb40751.x. (discussion 615\u20137).","journal-title":"Ann N Y Acad Sci"},{"issue":"14","key":"550_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2174\/138161209788168001","volume":"15","author":"F L\u00f3pez-Mu\u00f1oz","year":"2009","unstructured":"L\u00f3pez-Mu\u00f1oz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15(14):1563\u201386. https:\/\/doi.org\/10.2174\/138161209788168001.","journal-title":"Curr Pharm Des"},{"key":"550_CR23","first-page":"129","volume":"8","author":"HP Loomer","year":"1957","unstructured":"Loomer HP, Saunders JC, Kline NS. A clinical and pharmacodynamic evaluation of iproniazid as a psychic energizer. Psychiatr Res Rep Am Psychiatr Assoc. 1957;8:129\u201341.","journal-title":"Psychiatr Res Rep Am Psychiatr Assoc"},{"key":"550_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF02174413","volume":"8","author":"EA Zeller","year":"1952","unstructured":"Zeller EA, Barsky J, Fouts JR, Kirchheimer WF, Orden LS. Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experientia. 1952;8:349\u201350.","journal-title":"Experientia"},{"issue":"6","key":"550_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/BF00965519","volume":"7","author":"IC Campbell","year":"1982","unstructured":"Campbell IC, Marangos PJ, Parma A, Garrick NA, Murphy DL. Localization of monoamine oxidases A and B in primate brains relative to neuron-specific and non-neuronal enolases. Neurochem Res. 1982;7(6):657\u201366. https:\/\/doi.org\/10.1007\/BF00965519.","journal-title":"Neurochem Res"},{"issue":"10","key":"550_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40263-013-0097-3","volume":"27","author":"KI Shulman","year":"2013","unstructured":"Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013;27(10):789\u201397. https:\/\/doi.org\/10.1007\/s40263-013-0097-3.","journal-title":"CNS Drugs"},{"issue":"5","key":"550_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/00006842-199909000-00002","volume":"61","author":"EF Domino","year":"1999","unstructured":"Domino EF. History of modern psychopharmacology: a personal view with an emphasis on antidepressants. Psychosom Med. 1999;61(5):591\u20138. https:\/\/doi.org\/10.1097\/00006842-199909000-00002.","journal-title":"Psychosom Med"},{"issue":"5","key":"550_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1176\/ajp.115.5.459","volume":"115","author":"R Kuhn","year":"1958","unstructured":"Kuhn R. The treatment of depressive states with G 22355 (imipramine hydrochloride). Am J Psychiatry. 1958;115(5):459\u201364. https:\/\/doi.org\/10.1176\/ajp.115.5.459.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"550_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/BF02244985","volume":"114","author":"B Cusack","year":"1994","unstructured":"Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology. 1994;114(4):559\u201365. https:\/\/doi.org\/10.1007\/BF02244985.","journal-title":"Psychopharmacology"},{"issue":"3","key":"550_CR30","first-page":"1305","volume":"283","author":"MJ Owens","year":"1997","unstructured":"Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283(3):1305\u201322.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"550_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1023\/a:1006986824213","volume":"19","author":"C S\u00e1nchez","year":"1999","unstructured":"S\u00e1nchez C, Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol. 1999;19(4):467\u201389. https:\/\/doi.org\/10.1023\/a:1006986824213.","journal-title":"Cell Mol Neurobiol"},{"issue":"3","key":"550_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/0024-3205(74)90345-2","volume":"15","author":"DT Wong","year":"1974","unstructured":"Wong DT, Horng JS, Bymaster FP, Hauser KL, Molloy BB. A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sci. 1974;15(3):471\u20139. https:\/\/doi.org\/10.1016\/0024-3205(74)90345-2.","journal-title":"Life Sci"},{"issue":"3","key":"550_CR33","first-page":"804","volume":"193","author":"DT Wong","year":"1975","unstructured":"Wong DT, Bymaster FP, Horng JS, Molloy BB. A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine. J Pharmacol Exp Ther. 1975;193(3):804\u201311.","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"550_CR34","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nrd1821","volume":"4","author":"DT Wong","year":"2005","unstructured":"Wong DT, Perry KW, Bymaster FP. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov. 2005;4(9):764\u201374. https:\/\/doi.org\/10.1038\/nrd1821.","journal-title":"Nat Rev Drug Discov"},{"issue":"10128","key":"550_CR35","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(17)32802-7.","journal-title":"Lancet"},{"issue":"1","key":"550_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000110056","volume":"77","author":"CL Bockting","year":"2008","unstructured":"Bockting CL, ten Doesschate MC, Spijker J, Spinhoven P, Koeter MW, Schene AH, DELTA Study Group. Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom. 2008;77(1):17\u201326. https:\/\/doi.org\/10.1159\/000110056.","journal-title":"Psychother Psychosom"},{"issue":"11","key":"550_CR37","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1176\/ps.2009.60.11.1439","volume":"60","author":"BN Gaynes","year":"2009","unstructured":"Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439\u201345. https:\/\/doi.org\/10.1176\/ps.2009.60.11.1439.","journal-title":"Psychiatr Serv"},{"key":"550_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01661-0","author":"J Moncrieff","year":"2022","unstructured":"Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022. https:\/\/doi.org\/10.1038\/s41380-022-01661-0.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"550_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/2045125312445469","volume":"2","author":"E Penn","year":"2012","unstructured":"Penn E, Tracy DK. The drugs don\u2019t work? antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol. 2012;2(5):179\u201388. https:\/\/doi.org\/10.1177\/2045125312445469.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"550_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.neuropharm.2011.07.036","volume":"62","author":"G Sanacora","year":"2012","unstructured":"Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63\u201377. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.07.036.","journal-title":"Neuropharmacology"},{"issue":"4","key":"550_CR41","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF00345492","volume":"232","author":"JS Kim","year":"1982","unstructured":"Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr. 1982;232(4):299\u2013304. https:\/\/doi.org\/10.1007\/BF00345492.","journal-title":"Arch Psychiatr Nervenkr"},{"issue":"Suppl","key":"550_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0924-977x(95)00033-l","volume":"5","author":"C Altamura","year":"1995","unstructured":"Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol. 1995;5(Suppl):71\u20135. https:\/\/doi.org\/10.1016\/0924-977x(95)00033-l.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"550_CR43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00228-009-0650-7","volume":"65","author":"E K\u00fc\u00e7\u00fckibrahimo\u011flu","year":"2009","unstructured":"K\u00fc\u00e7\u00fckibrahimo\u011flu E, Saygin MZ, Cali\u015fkan M, Kaplan OK, Unsal C, G\u00f6ren MZ. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- or S-citalopram-treated female patients with major depression. Eur J Clin Pharmacol. 2009;65(6):571\u20137. https:\/\/doi.org\/10.1007\/s00228-009-0650-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"550_CR44","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.pnpbp.2006.03.036","volume":"30","author":"H Mitani","year":"2006","unstructured":"Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1155\u20138. https:\/\/doi.org\/10.1016\/j.pnpbp.2006.03.036.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"12","key":"550_CR45","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","volume":"73","author":"JH Krystal","year":"2013","unstructured":"Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013;73(12):1133\u201341. https:\/\/doi.org\/10.1016\/j.biopsych.2013.03.026.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"550_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0014-2999(90)90204-j","volume":"185","author":"R Trullas","year":"1990","unstructured":"Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185(1):1\u201310. https:\/\/doi.org\/10.1016\/0014-2999(90)90204-j.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20132","key":"550_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s0091-3057(01)00693-1","volume":"71","author":"A Yilmaz","year":"2002","unstructured":"Yilmaz A, Schulz D, Aksoy A, Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav. 2002;71(1\u20132):341\u20134. https:\/\/doi.org\/10.1016\/s0091-3057(01)00693-1.","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"550_CR48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.tips.2009.09.002","volume":"30","author":"P Skolnick","year":"2009","unstructured":"Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30(11):563\u20139. https:\/\/doi.org\/10.1016\/j.tips.2009.09.002.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"550_CR49","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/s0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351\u20134. https:\/\/doi.org\/10.1016\/s0006-3223(99)00230-9.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"550_CR50","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856\u201364. https:\/\/doi.org\/10.1001\/archpsyc.63.8.856.","journal-title":"Arch Gen Psychiatry"},{"issue":"277","key":"550_CR51","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","volume":"1","author":"WS Marcantoni","year":"2020","unstructured":"Marcantoni WS, Akoumba BS, Wassef M, Mayrand J, Lai H, Richard-Devantoy S, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. J Affect Disord. 2020;1(277):831\u201341. https:\/\/doi.org\/10.1016\/j.jad.2020.09.007.","journal-title":"J Affect Disord"},{"issue":"12","key":"550_CR52","doi-asserted-by":"publisher","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","volume":"27","author":"RB Price","year":"2022","unstructured":"Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry. 2022;27(12):5096\u2013112. https:\/\/doi.org\/10.1038\/s41380-022-01757-7.","journal-title":"Mol Psychiatry"},{"key":"550_CR53","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1146\/annurev-med-053013-062946","volume":"66","author":"CG Abdallah","year":"2015","unstructured":"Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med. 2015;66:509\u201323. https:\/\/doi.org\/10.1146\/annurev-med-053013-062946.","journal-title":"Annu Rev Med"},{"issue":"44","key":"550_CR54","doi-asserted-by":"publisher","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","volume":"36","author":"CF Zorumski","year":"2016","unstructured":"Zorumski CF, Izumi Y, Mennerick S. Ketamine: NMDA receptors and beyond. J Neurosci. 2016;36(44):11158\u201364. https:\/\/doi.org\/10.1523\/JNEUROSCI.1547-16.2016.","journal-title":"J Neurosci"},{"issue":"12","key":"550_CR55","doi-asserted-by":"publisher","first-page":"6713","DOI":"10.3390\/ijms23126713","volume":"23","author":"A Wojtas","year":"2022","unstructured":"Wojtas A, Bysiek A, Wawrzczak-Bargiela A, Szych Z, Majcher-Ma\u015blanka I, Herian M, et al. Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior. Int J Mol Sci. 2022;23(12):6713. https:\/\/doi.org\/10.3390\/ijms23126713.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"550_CR56","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.biopsych.2011.11.006","volume":"71","author":"GM Chowdhury","year":"2012","unstructured":"Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-nuclear magnetic resonance spectroscopy measures of ketamine\u2019s effect on amino acid neurotransmitter metabolism. Biol Psychiatry. 2012;71(11):1022\u20135. https:\/\/doi.org\/10.1016\/j.biopsych.2011.11.006.","journal-title":"Biol Psychiatry"},{"issue":"5994","key":"550_CR57","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1126\/science.1190287","volume":"329","author":"N Li","year":"2010","unstructured":"Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959\u201364. https:\/\/doi.org\/10.1126\/science.1190287.","journal-title":"Science"},{"issue":"8","key":"550_CR58","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","volume":"69","author":"N Li","year":"2011","unstructured":"Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69(8):754\u201361. https:\/\/doi.org\/10.1016\/j.biopsych.2010.12.015.","journal-title":"Biol Psychiatry"},{"issue":"6","key":"550_CR59","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","volume":"45","author":"CG Abdallah","year":"2020","unstructured":"Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, et al. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology. 2020;45(6):990\u20137. https:\/\/doi.org\/10.1038\/s41386-020-0644-9.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"550_CR60","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fnhum.2016.00612","volume":"29","author":"L Li","year":"2016","unstructured":"Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016;29(10):612. https:\/\/doi.org\/10.3389\/fnhum.2016.00612.","journal-title":"Front Hum Neurosci"},{"issue":"4","key":"550_CR61","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1017\/S0954579406060585","volume":"18","author":"ME Thase","year":"2006","unstructured":"Thase ME. Bipolar depression: diagnostic and treatment considerations. Dev Psychopathol. 2006;18(4):1213\u201330. https:\/\/doi.org\/10.1017\/S0954579406060585.","journal-title":"Dev Psychopathol"},{"issue":"11","key":"550_CR62","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.4088\/JCP.09r05259gre","volume":"71","author":"G Salvadore","year":"2010","unstructured":"Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA Jr. The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry. 2010;71(11):1488\u2013501. https:\/\/doi.org\/10.4088\/JCP.09r05259gre.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"550_CR63","doi-asserted-by":"publisher","first-page":"454","DOI":"10.4103\/0253-7613.161277","volume":"47","author":"G Banwari","year":"2015","unstructured":"Banwari G, Desai P, Patidar P. Ketamine-induced affective switch in a patient with treatment-resistant depression. Indian J Pharmacol. 2015;47(4):454\u20135. https:\/\/doi.org\/10.4103\/0253-7613.161277.","journal-title":"Indian J Pharmacol"},{"issue":"8","key":"550_CR64","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14740338.2020.1776699","volume":"19","author":"NB Rodrigues","year":"2020","unstructured":"Rodrigues NB, McIntyre RS, Lipsitz O, Lee Y, Cha DS, Nasri F, et al. Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. Expert Opin Drug Saf. 2020;19(8):1031\u201340. https:\/\/doi.org\/10.1080\/14740338.2020.1776699.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"550_CR65","first-page":"15","volume":"4","author":"P Lee","year":"2009","unstructured":"Lee P, Ong T, Chua C, Lei C, Teh G. Street ketamine-associated bladder dysfunction: an emerging health problem. Malays Fam Physician. 2009;4(1):15\u20138.","journal-title":"Malays Fam Physician"},{"issue":"3","key":"550_CR66","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4088\/JCP.13m08852","volume":"76","author":"LB Wan","year":"2015","unstructured":"Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2015;76(3):247\u201352. https:\/\/doi.org\/10.4088\/JCP.13m08852.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"550_CR67","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/HRP.0000000000000179","volume":"26","author":"DF Ionescu","year":"2018","unstructured":"Ionescu DF, Felicione JM, Gosai A, Cusin C, Shin P, Shapero BG, et al. Ketamine-associated brain changes: a review of the neuroimaging literature. Harv Rev Psychiatry. 2018;26(6):320\u201339. https:\/\/doi.org\/10.1097\/HRP.0000000000000179.","journal-title":"Harv Rev Psychiatry"},{"issue":"5","key":"550_CR68","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40263-018-0519-3","volume":"32","author":"P Molero","year":"2018","unstructured":"Molero P, Ramos-Quiroga JA, Martin-Santos R, Calvo-S\u00e1nchez E, Guti\u00e9rrez-Rojas L, Meana JJ. Antidepressant efficacy and tolerability of ketamine and esketamine: a critical review. CNS Drugs. 2018;32(5):411\u201320. https:\/\/doi.org\/10.1007\/s40263-018-0519-3.","journal-title":"CNS Drugs"},{"issue":"4","key":"550_CR69","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","volume":"74","author":"G Sanacora","year":"2017","unstructured":"Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al. American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiat. 2017;74(4):399\u2013405. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.0080.","journal-title":"JAMA Psychiat"},{"issue":"6","key":"550_CR70","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","volume":"21","author":"S Nikayin","year":"2022","unstructured":"Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opin Drug Saf. 2022;21(6):777\u201387. https:\/\/doi.org\/10.1080\/14740338.2022.2066651.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"550_CR71","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.tins.2020.11.008","volume":"44","author":"NK Savalia","year":"2021","unstructured":"Savalia NK, Shao LX, Kwan AC. A dendrite-focused framework for understanding the actions of ketamine and psychedelics. Trends Neurosci. 2021;44(4):260\u201375. https:\/\/doi.org\/10.1016\/j.tins.2020.11.008.","journal-title":"Trends Neurosci"},{"issue":"11","key":"550_CR72","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/s41593-022-01177-4","volume":"25","author":"AC Kwan","year":"2022","unstructured":"Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci. 2022;25(11):1407\u201319. https:\/\/doi.org\/10.1038\/s41593-022-01177-4.","journal-title":"Nat Neurosci"},{"issue":"5","key":"550_CR73","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","volume":"184","author":"PC Casarotto","year":"2021","unstructured":"Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184(5):1299-1313.e19. https:\/\/doi.org\/10.1016\/j.cell.2021.01.034.","journal-title":"Cell"},{"issue":"6","key":"550_CR74","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26(6):1032\u201341. https:\/\/doi.org\/10.1038\/s41593-023-01316-5.","journal-title":"Nat Neurosci"},{"issue":"11","key":"550_CR75","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170\u201382. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.022.","journal-title":"Cell Rep"},{"key":"550_CR76","first-page":"208","volume-title":"Plants of the gods: their sacred, healing, and hallucinogenic powers","author":"RE Schultes","year":"1998","unstructured":"Schultes RE, Hofmann A, R\u00e4tsch C. Plants of the gods: their sacred, healing, and hallucinogenic powers. Fairfield: Healing Arts Press; 1998. p. 208."},{"issue":"2","key":"550_CR77","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478. (Erratum in: Pharmacol Rev. 2016 Apr;68(2):356).","journal-title":"Pharmacol Rev"},{"issue":"4","key":"550_CR78","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1055\/a-1310-3990","volume":"54","author":"DE Nichols","year":"2021","unstructured":"Nichols DE, Walter H. The history of psychedelics in psychiatry. Pharmacopsychiatry. 2021;54(4):151\u201366. https:\/\/doi.org\/10.1055\/a-1310-3990.","journal-title":"Pharmacopsychiatry"},{"issue":"1\u20132","key":"550_CR79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/02791072.1979.10472092","volume":"11","author":"A Hofmann","year":"1979","unstructured":"Hofmann A. How LSD originated. J Psychedelic Drugs. 1979;11(1\u20132):53\u201360. https:\/\/doi.org\/10.1080\/02791072.1979.10472092.","journal-title":"J Psychedelic Drugs"},{"issue":"11","key":"550_CR80","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/npp.2017.86","volume":"42","author":"ME Liechti","year":"2017","unstructured":"Liechti ME. Modern clinical research on LSD. Neuropsychopharmacology. 2017;42(11):2114\u201327. https:\/\/doi.org\/10.1038\/npp.2017.86.","journal-title":"Neuropsychopharmacology"},{"key":"550_CR81","volume-title":"Psychedelic drugs reconsidered","author":"L Grinspoon","year":"1979","unstructured":"Grinspoon L, Bakalar JB. Psychedelic drugs reconsidered. New York: Basic Books; 1979."},{"issue":"2","key":"550_CR82","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/002076407001600204","volume":"16","author":"G Fisher","year":"1970","unstructured":"Fisher G. The psycholytic treatment of a childhood schizophrenic girl. Int J Soc Psychiatry. 1970;16(2):112\u201330. https:\/\/doi.org\/10.1177\/002076407001600204.","journal-title":"Int J Soc Psychiatry"},{"issue":"11","key":"550_CR83","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","volume":"212","author":"WN Pahnke","year":"1970","unstructured":"Pahnke WN, Kurland AA, Unger S, Savage C, Grof S. The experimental use of psychedelic (LSD) psychotherapy. JAMA. 1970;212(11):1856\u201363.","journal-title":"JAMA"},{"issue":"3","key":"550_CR84","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.neuropharm.2011.01.017","volume":"61","author":"AL Halberstadt","year":"2011","unstructured":"Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61(3):364\u201381. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.01.017.","journal-title":"Neuropharmacology"},{"issue":"1","key":"550_CR85","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/BF00443425","volume":"97","author":"PA Pierce","year":"1989","unstructured":"Pierce PA, Peroutka SJ. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex. Psychopharmacology. 1989;97(1):118\u201322. https:\/\/doi.org\/10.1007\/BF00443425.","journal-title":"Psychopharmacology"},{"issue":"2","key":"550_CR86","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF00176847","volume":"94","author":"M Titeler","year":"1988","unstructured":"Titeler M, Lyon RA, Glennon RA. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology. 1988;94(2):213\u20136. https:\/\/doi.org\/10.1007\/BF00176847.","journal-title":"Psychopharmacology"},{"issue":"1","key":"550_CR87","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/00223980.1956.9916206","volume":"41","author":"HA Abramson","year":"1959","unstructured":"Abramson HA, Jarvik ME, Gorin MH, Hirsch MW. Lysergic acid diethylamide (LSD-25): XVII. Tolerance development and its relationship to a theory of psychosis. J Psychol. 1959;41(1):81\u2013105. https:\/\/doi.org\/10.1080\/00223980.1956.9916206.","journal-title":"J Psychol"},{"issue":"3","key":"550_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF00421802","volume":"36","author":"B Angrist","year":"1974","unstructured":"Angrist B, Rotrosen J, Gershon S. Assessment of tolerance to the hallucinogenic effects of DOM. Psychopharmacologia. 1974;36(3):203\u20137. https:\/\/doi.org\/10.1007\/BF00421802.","journal-title":"Psychopharmacologia"},{"issue":"3","key":"550_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00413101","volume":"12","author":"AB Wolbach Jr","year":"1962","unstructured":"Wolbach AB Jr, Isbell H, Miner EJ. Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions. Psychopharmacologia. 1962;12(3):1\u201314. https:\/\/doi.org\/10.1007\/BF00413101.","journal-title":"Psychopharmacologia"},{"issue":"3","key":"550_CR90","first-page":"1373","volume":"278","author":"GJ Marek","year":"1996","unstructured":"Marek GJ, Aghajanian GK. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex. J Pharmacol Exp Ther. 1996;278(3):1373\u201382.","journal-title":"J Pharmacol Exp Ther"},{"issue":"25","key":"550_CR91","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35(25):2505\u201311. https:\/\/doi.org\/10.1016\/0024-3205(84)90436-3.","journal-title":"Life Sci"},{"issue":"8","key":"550_CR92","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/00008877-199512000-00010","volume":"6","author":"TE Sipes","year":"1995","unstructured":"Sipes TE, Geyer MA. DOI disruption of prepulse inhibition of startle in the rat is mediated by 5-HT(2A) and not by 5-HT(2C) receptors. Behav Pharmacol. 1995;6(8):839\u201342.","journal-title":"Behav Pharmacol"},{"issue":"2","key":"550_CR93","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/0006-8993(91)90099-h","volume":"552","author":"EL Barker","year":"1991","unstructured":"Barker EL, Burris KD, Sanders-Bush E. Phosphoinositide hydrolysis linked 5-HT2 receptors in fibroblasts from choroid plexus. Brain Res. 1991;552(2):330\u20132. https:\/\/doi.org\/10.1016\/0006-8993(91)90099-h.","journal-title":"Brain Res"},{"issue":"7","key":"550_CR94","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenb\u00e6k DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1328\u201334. https:\/\/doi.org\/10.1038\/s41386-019-0324-9.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"550_CR95","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/a-1721-2914","volume":"55","author":"FX Vollenweider","year":"2022","unstructured":"Vollenweider FX, Smallridge JW. Classic psychedelic drugs: update on biological mechanisms. Pharmacopsychiatry. 2022;55(3):121\u201338. https:\/\/doi.org\/10.1055\/a-1721-2914.","journal-title":"Pharmacopsychiatry"},{"key":"550_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.116980","volume":"218","author":"FS Barrett","year":"2020","unstructured":"Barrett FS, Krimmel SR, Griffiths RR, Seminowicz DA, Mathur BN. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage. 2020;218: 116980. https:\/\/doi.org\/10.1016\/j.neuroimage.2020.116980.","journal-title":"Neuroimage"},{"issue":"8","key":"550_CR97","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.biopsych.2014.04.010","volume":"78","author":"R Kraehenmann","year":"2015","unstructured":"Kraehenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2015;78(8):572\u201381. https:\/\/doi.org\/10.1016\/j.biopsych.2014.04.010.","journal-title":"Biol Psychiatry"},{"issue":"7","key":"550_CR98","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35082","volume":"25","author":"KH Preller","year":"2018","unstructured":"Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, St\u00e4mpfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;25(7): e35082. https:\/\/doi.org\/10.7554\/eLife.35082.","journal-title":"Elife"},{"issue":"8","key":"550_CR99","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnhum.2014.00020","volume":"3","author":"RL Carhart-Harris","year":"2014","unstructured":"Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;3(8):20. https:\/\/doi.org\/10.3389\/fnhum.2014.00020.","journal-title":"Front Hum Neurosci"},{"issue":"3","key":"550_CR100","first-page":"183","volume":"120","author":"JC Klock","year":"1974","unstructured":"Klock JC, Boerner U, Becker CE. Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases. West J Med. 1974;120(3):183\u20138.","journal-title":"West J Med"},{"issue":"10","key":"550_CR101","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","volume":"172","author":"RJ Strassman","year":"1984","unstructured":"Strassman RJ. Adverse reactions to psychedelic drugs: a review of the literature. J Nerv Ment Dis. 1984;172(10):577\u201395.","journal-title":"J Nerv Ment Dis"},{"issue":"5","key":"550_CR102","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S0893-133X(01)00405-5","volume":"26","author":"CD Nichols","year":"2002","unstructured":"Nichols CD, Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. Neuropsychopharmacology. 2002;26(5):634\u201342. https:\/\/doi.org\/10.1016\/S0893-133X(01)00405-5.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"550_CR103","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434\u201352. https:\/\/doi.org\/10.1177\/0269881110382466.","journal-title":"J Psychopharmacol"},{"key":"550_CR104","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.forsciint.2018.01.006","volume":"284","author":"DE Nichols","year":"2018","unstructured":"Nichols DE, Grob CS. Is LSD toxic? Forensic Sci Int. 2018;284:141\u20135. https:\/\/doi.org\/10.1016\/j.forsciint.2018.01.006.","journal-title":"Forensic Sci Int"},{"issue":"3","key":"550_CR105","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/02698811211069100","volume":"36","author":"AK Schlag","year":"2022","unstructured":"Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: from anecdotes and misinformation to systematic science. J Psychopharmacol. 2022;36(3):258\u201372. https:\/\/doi.org\/10.1177\/02698811211069100.","journal-title":"J Psychopharmacol"},{"key":"550_CR106","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-106070","author":"WR Smith","year":"2020","unstructured":"Smith WR, Sisti D. Ethics and ego dissolution: the case of psilocybin. J Med Ethics. 2020. https:\/\/doi.org\/10.1136\/medethics-2020-106070.","journal-title":"J Med Ethics"},{"issue":"12","key":"550_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.727117","volume":"4","author":"MV Vargas","year":"2021","unstructured":"Vargas MV, Meyer R, Avanes AA, Rus M, Olson DE. Psychedelics and other psychoplastogens for treating mental illness. Front Psychiatry. 2021;4(12): 727117. https:\/\/doi.org\/10.3389\/fpsyt.2021.727117.","journal-title":"Front Psychiatry"},{"issue":"46","key":"550_CR108","doi-asserted-by":"publisher","first-page":"19575","DOI":"10.1073\/pnas.0905884106","volume":"106","author":"KA Jones","year":"2009","unstructured":"Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci USA. 2009;106(46):19575\u201380. https:\/\/doi.org\/10.1073\/pnas.0905884106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"550_CR109","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1021\/acsptsci.0c00065","volume":"4","author":"C Ly","year":"2020","unstructured":"Ly C, Greb AC, Vargas MV, Duim WC, Grodzki ACG, Lein PJ, et al. Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth. ACS Pharmacol Transl Sci. 2020;4(2):452\u201360. https:\/\/doi.org\/10.1021\/acsptsci.0c00065.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"6633","key":"550_CR110","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379(6633):700\u20136. https:\/\/doi.org\/10.1126\/science.adf0435.","journal-title":"Science"},{"issue":"3","key":"550_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021","volume":"37","author":"RM de la Fuente","year":"2021","unstructured":"de la Fuente RM, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37(3): 109836. https:\/\/doi.org\/10.1016\/j.celrep.2021.","journal-title":"Cell Rep"},{"issue":"2","key":"550_CR112","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0133-15.2016","volume":"3","author":"V Phoumthipphavong","year":"2016","unstructured":"Phoumthipphavong V, Barthas F, Hassett S, Kwan AC. Longitudinal effects of ketamine on dendritic architecture in vivo in the mouse medial frontal cortex. eNeuro. 2016;3(2): ENEURO.0133-15.2016. https:\/\/doi.org\/10.1523\/ENEURO.0133-15.2016.","journal-title":"eNeuro"},{"issue":"7842","key":"550_CR113","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589(7842):474\u20139. https:\/\/doi.org\/10.1038\/s41586-020-3008-z.","journal-title":"Nature"},{"issue":"16","key":"550_CR114","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535\u201325444. https:\/\/doi.org\/10.1016\/j.neuron.2021.06.008.","journal-title":"Neuron"},{"issue":"9","key":"550_CR115","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41386-023-01572-w","volume":"48","author":"SJ Jefferson","year":"2023","unstructured":"Jefferson SJ, Gregg I, Dibbs M, Liao C, Wu H, Davoudian PA, et al. 5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice. Neuropsychopharmacology. 2023;48(9):1257\u201366. https:\/\/doi.org\/10.1038\/s41386-023-01572-w.","journal-title":"Neuropsychopharmacology"},{"issue":"6579","key":"550_CR116","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.abl8615","volume":"375","author":"D Cao","year":"2022","unstructured":"Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science. 2022;375(6579):403\u201311. https:\/\/doi.org\/10.1126\/science.abl8615.","journal-title":"Science"},{"issue":"3","key":"550_CR117","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1021\/acs.jmedchem.9b01404","volume":"63","author":"LE Dunlap","year":"2020","unstructured":"Dunlap LE, Azinfar A, Ly C, Cameron LP, Viswanathan J, Tombari RJ, et al. Identification of psychoplastogenic N,N-dimethylaminoisotryptamine (isoDMT) analogues through structure-activity relationship studies. J Med Chem. 2020;63(3):1142\u201355. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01404.","journal-title":"J Med Chem"},{"issue":"11","key":"550_CR118","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1038\/s41380-021-01159-1","volume":"26","author":"J Lu","year":"2021","unstructured":"Lu J, Tjia M, Mullen B, Cao B, Lukasiewicz K, Shah-Morales S, et al. An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. Mol Psychiatry. 2021;26(11):6237\u201352. https:\/\/doi.org\/10.1038\/s41380-021-01159-1.","journal-title":"Mol Psychiatry"},{"key":"550_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173500","volume":"222","author":"Y Qu","year":"2023","unstructured":"Qu Y, Chang L, Ma L, Wan X, Hashimoto K. Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice. Pharmacol Biochem Behav. 2023;222: 173500. https:\/\/doi.org\/10.1016\/j.pbb.2022.173500.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"550_CR120","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268\u201383. https:\/\/doi.org\/10.1007\/s00213-006-0457-5.","journal-title":"Psychopharmacology"},{"issue":"6","key":"550_CR121","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0269881108094300","volume":"22","author":"R Griffiths","year":"2008","unstructured":"Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621\u201332. https:\/\/doi.org\/10.1177\/0269881108094300.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"550_CR122","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology. 2011;218(4):649\u201365. https:\/\/doi.org\/10.1007\/s00213-011-2358-5.","journal-title":"Psychopharmacology"},{"issue":"12","key":"550_CR123","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397. https:\/\/doi.org\/10.1177\/0269881116675513.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"550_CR124","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157\u201364. https:\/\/doi.org\/10.2174\/1874473708666150107121331.","journal-title":"Curr Drug Abuse Rev"},{"issue":"3","key":"550_CR125","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1177\/0269881114565144","volume":"29","author":"MP Bogenschutz","year":"2015","unstructured":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289\u201399. https:\/\/doi.org\/10.1177\/0269881114565144.","journal-title":"J Psychopharmacol"},{"issue":"8","key":"550_CR126","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fphar.2017.00974","volume":"17","author":"L Roseman","year":"2018","unstructured":"Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;17(8):974. https:\/\/doi.org\/10.3389\/fphar.2017.00974.","journal-title":"Front Pharmacol"},{"issue":"5","key":"550_CR127","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/acps.12904","volume":"138","author":"D Erritzoe","year":"2018","unstructured":"Erritzoe D, Roseman L, Nour MM, MacLean K, Kaelen M, Nutt DJ, et al. Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand. 2018;138(5):368\u201378. https:\/\/doi.org\/10.1111\/acps.12904.","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"550_CR128","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","volume":"30","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268\u201378. https:\/\/doi.org\/10.1177\/0269881116662634.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"550_CR129","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2020","unstructured":"Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2020;4(2):568\u201372. https:\/\/doi.org\/10.1021\/acsptsci.0c00194.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"7","key":"550_CR130","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513\u201320. https:\/\/doi.org\/10.1097\/NMD.0000000000000113.","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"550_CR131","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0269881114555249","volume":"29","author":"P Gasser","year":"2015","unstructured":"Gasser P, Kirchner K, Passie T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J Psychopharmacol. 2015;29(1):57\u201368. https:\/\/doi.org\/10.1177\/0269881114555249.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"550_CR132","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","volume":"26","author":"TS Krebs","year":"2012","unstructured":"Krebs TS, Johansen P\u00d8. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994\u20131002. https:\/\/doi.org\/10.1177\/0269881112439253.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"550_CR133","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0269881120940937","volume":"35","author":"JG Ramaekers","year":"2021","unstructured":"Ramaekers JG, Hutten N, Mason NL, Dolder P, Theunissen EL, Holze F, et al. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. J Psychopharmacol. 2021;35(4):398\u2013405. https:\/\/doi.org\/10.1177\/0269881120940937.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"550_CR134","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","volume":"66","author":"RA Sewell","year":"2006","unstructured":"Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920\u20132. https:\/\/doi.org\/10.1212\/01.wnl.0000219761.05466.43.","journal-title":"Neurology"},{"issue":"8","key":"550_CR135","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11916-022-01063-5","volume":"26","author":"SS Rusanen","year":"2022","unstructured":"Rusanen SS, De S, Schindler EAD, Artto VA, Storvik M. Self-reported efficacy of treatments in cluster headache: a systematic review of survey studies. Curr Pain Headache Rep. 2022;26(8):623\u201337. https:\/\/doi.org\/10.1007\/s11916-022-01063-5.","journal-title":"Curr Pain Headache Rep"},{"issue":"5","key":"550_CR136","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","volume":"20","author":"FX Vollenweider","year":"1999","unstructured":"Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man\u2014A PET study with [11C]raclopride. Neuropsychopharmacology. 1999;20(5):424\u201333. https:\/\/doi.org\/10.1016\/S0893-133X(98)00108-0.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"550_CR137","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s0924-9338(00)00520-4","volume":"15","author":"F Salom\u00e9","year":"2000","unstructured":"Salom\u00e9 F, Boyer P, Fayol M. The effects of psychoactive drugs and neuroleptics on language in normal subjects and schizophrenic patients: a review. Eur Psychiatry. 2000;15(8):461\u20139. https:\/\/doi.org\/10.1016\/s0924-9338(00)00520-4.","journal-title":"Eur Psychiatry"},{"issue":"2","key":"550_CR138","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology. 2004;172(2):145\u201356. https:\/\/doi.org\/10.1007\/s00213-003-1640-6.","journal-title":"Psychopharmacology"},{"issue":"1","key":"550_CR139","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71\u20138. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.116.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"550_CR140","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165\u201380. https:\/\/doi.org\/10.1177\/0269881116675512.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"550_CR141","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/0269881114548296","volume":"28","author":"MW Johnson","year":"2014","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983\u201392. https:\/\/doi.org\/10.1177\/0269881114548296.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"550_CR142","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","volume":"43","author":"MW Johnson","year":"2017","unstructured":"Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43(1):55\u201360. https:\/\/doi.org\/10.3109\/00952990.2016.1170135.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"10","key":"550_CR143","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiat. 2022;79(10):953\u201362. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.2096.","journal-title":"JAMA Psychiat"},{"key":"550_CR144","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3:619\u201327. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7.","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"550_CR145","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235(2):399\u2013408. https:\/\/doi.org\/10.1007\/s00213-017-4771-x.","journal-title":"Psychopharmacology"},{"issue":"5","key":"550_CR146","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2021;78(5):481\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"550_CR147","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/02698811211073759","volume":"36","author":"N Gukasyan","year":"2022","unstructured":"Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151\u20138. https:\/\/doi.org\/10.1177\/02698811211073759.","journal-title":"J Psychopharmacol"},{"issue":"15","key":"550_CR148","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402\u201311. https:\/\/doi.org\/10.1056\/NEJMoa2032994.","journal-title":"N Engl J Med"},{"issue":"5","key":"550_CR149","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2022.565","volume":"8","author":"T Barba","year":"2022","unstructured":"Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, et al. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open. 2022;8(5): e163. https:\/\/doi.org\/10.1192\/bjo.2022.565.","journal-title":"BJPsych Open"},{"issue":"9","key":"550_CR150","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1177\/0269881117725915","volume":"31","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Nutt DJ. Serotonin and brain function: a tale of two receptors. J Psychopharmacol. 2017;31(9):1091\u2013120. https:\/\/doi.org\/10.1177\/0269881117725915.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"550_CR151","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4088\/jcp.v67n1110","volume":"67","author":"FA Moreno","year":"2006","unstructured":"Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735\u201340. https:\/\/doi.org\/10.4088\/jcp.v67n1110.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"550_CR152","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/hbm.21381","volume":"33","author":"DB de Araujo","year":"2012","unstructured":"de Araujo DB, Ribeiro S, Cecchi GA, Carvalho FM, Sanchez TA, Pinto JP, et al. Seeing with the eyes shut: neural basis of enhanced imagery following Ayahuasca ingestion. Hum Brain Mapp. 2012;33(11):2550\u201360. https:\/\/doi.org\/10.1002\/hbm.21381.","journal-title":"Hum Brain Mapp"},{"issue":"6","key":"550_CR153","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1073\/pnas.0812686106","volume":"106","author":"YI Sheline","year":"2009","unstructured":"Sheline YI, Barch DM, Price JL, Rundle MM, Vaishnavi SN, Snyder AZ, et al. The default mode network and self-referential processes in depression. Proc Natl Acad Sci USA. 2009;106(6):1942\u20137. https:\/\/doi.org\/10.1073\/pnas.0812686106.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"550_CR154","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00213-006-0358-7","volume":"186","author":"J Riba","year":"2006","unstructured":"Riba J, Romero S, Grasa E, Mena E, Carri\u00f3 I, Barbanoj MJ. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology. 2006;186(1):93\u20138. https:\/\/doi.org\/10.1007\/s00213-006-0358-7.","journal-title":"Psychopharmacology"},{"issue":"6","key":"550_CR155","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1073\/pnas.1119598109","volume":"109","author":"RL Carhart-Harris","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA. 2012;109(6):2138\u201343. https:\/\/doi.org\/10.1073\/pnas.1119598109.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"550_CR156","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.1073\/pnas.1518377113","volume":"113","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci USA. 2016;113(17):4853\u20138. https:\/\/doi.org\/10.1073\/pnas.1518377113.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"550_CR157","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1590\/1516-4446-2014-1496","volume":"37","author":"FL Os\u00f3rio","year":"2015","unstructured":"Os\u00f3rio FL, Sanches RF, Macedo LR, Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, Araujo DB, Riba J, Crippa JA, Hallak JE. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Braz J Psychiatry. 2015;37(1):13\u201320. https:\/\/doi.org\/10.1590\/1516-4446-2014-1496.","journal-title":"Braz J Psychiatry"},{"issue":"1","key":"550_CR158","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF, de Lima OF, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol. 2016;36(1):77\u201381. https:\/\/doi.org\/10.1097\/JCP.0000000000000436.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"550_CR159","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655\u201363. https:\/\/doi.org\/10.1017\/S0033291718001356.","journal-title":"Psychol Med"},{"issue":"Pt 1","key":"550_CR160","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainresbull.2016.04.016","volume":"126","author":"TM Carbonaro","year":"2016","unstructured":"Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. Brain Res Bull. 2016;126(Pt 1):74\u201388. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.04.016.","journal-title":"Brain Res Bull"},{"issue":"4","key":"550_CR161","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/02791072.2019","volume":"51","author":"AV Rodrigues","year":"2019","unstructured":"Rodrigues AV, Almeida FJ, Vieira-Coelho MA. Dimethyltryptamine: endogenous role and therapeutic potential. J Psychoactive Drugs. 2019;51(4):299\u2013310. https:\/\/doi.org\/10.1080\/02791072.2019.","journal-title":"J Psychoactive Drugs"},{"issue":"2","key":"550_CR162","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/00952990.2018.1545024","volume":"45","author":"AK Davis","year":"2019","unstructured":"Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse. 2019;45(2):161\u20139. https:\/\/doi.org\/10.1080\/00952990.2018.1545024.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"12","key":"550_CR163","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.760671","volume":"25","author":"J Reckweg","year":"2021","unstructured":"Reckweg J, Mason NL, van Leeuwen C, Toennes SW, Terwey TH, Ramaekers JG. A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in healthy volunteers. Front Pharmacol. 2021;25(12): 760671. https:\/\/doi.org\/10.3389\/fphar.2021.760671.","journal-title":"Front Pharmacol"},{"issue":"1","key":"550_CR164","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/jnc.15587","volume":"162","author":"JT Reckweg","year":"2022","unstructured":"Reckweg JT, Uthaug MV, Szabo A, Davis AK, Lancelotta R, Mason NL, et al. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT). J Neurochem. 2022;162(1):128\u201346. https:\/\/doi.org\/10.1111\/jnc.15587.","journal-title":"J Neurochem"},{"issue":"4","key":"550_CR165","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.2487","volume":"111","author":"AM Becker","year":"2022","unstructured":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clin Pharmacol Ther. 2022;111(4):886\u201395. https:\/\/doi.org\/10.1002\/cpt.2487.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00550-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-023-00550-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-023-00550-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T05:38:04Z","timestamp":1700545084000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-023-00550-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":165,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["550"],"URL":"https:\/\/doi.org\/10.1007\/s43440-023-00550-9","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"30 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}